Try our beta test site

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Hoosier Cancer Research Network
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Matthew Galsky, Hoosier Cancer Research Network
ClinicalTrials.gov Identifier:
NCT01215136
First received: October 4, 2010
Last updated: February 6, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2018
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)